Table 2. Meta-analysis and heterogeneity test of the CYP2D6 gene polymorphisms on PD risk.
| Comparisons | No. of study | No. of patient | A vs. G |
AA vs. GG |
AG vs. GG |
AG + AA vs. GG |
AA vs. AG + GG |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR(95%CI) | I2(%) | OR(95%CI) | I2(%) | OR(95%CI) | I2(%) | OR(95%CI) | I2(%) | OR(95%CI) | I2(%) | |||
| overall | 22 | 2629 | 1.28(1.14-1.43) | 38.7 | 1.43(1.06-1.93) | 0.0 | 1.22(1.06-1.40) | 29.8 | 1.26(1.10-1.44) | 23.1 | 1.37(1.02-1.83) | 0.0 |
| subgroup | ||||||||||||
| Sporadic/Familial PD(S/F/NR) | ||||||||||||
| S | 13 | 1932 | 1.15(1.00-1.32) | 17.6 | 1.40(1.00-1.96) | 11.0 | 1.06(0.89-1.25) | 13.4 | 1.11(0.95-1.30) | 0.0 | 1.37(0.98-1.92) | 21.0 |
| F | 6 | 278 | 1.40(1.04-1.88) | 74.1 | 1.13(0.56-2.29) | 26.4 | 1.50(1.04-2.16) | 58.1 | 1.44(1.02-2.03) | 64.6 | 1.33(1.00-1.78) | 2.7 |
| NA | 5 | 419 | 1.65(1.24-2.20) | 23.4 | 1.80(0.71-4.59) | 9.5 | 1.62(1.17-2.26) | 0.0 | 1.65(1.19-2.27) | 0.0 | 1.61(0.64-4.08) | 3.9 |
| Early/Late-onset PD(E/L/NA) | ||||||||||||
| E | 4 | 265 | 0.84(0.62-1.14) | 85.1 | 0.60(0.28-1.27) | 0.0 | 0.97(0.67-1.41) | 80.8 | 0.90(0.63-1.28) | 81.1 | 0.66(0.32-1.50) | 0.0 |
| L | 5 | 660 | 1.15(0.93-1.42) | 74.4 | 0.87(0.52-1.47) | 37.8 | 1.28(0.98-1.66) | 34.6 | 1.20(0.94-1.54) | 55.2 | 0.80(0.48-1.33) | 5.9 |
| NA | 16 | 1694 | 1.32(1.14-1.53) | 33.9 | 1.67(1.14-2.45) | 0.0 | 1.23(1.03-1.46) | 31.9 | 1.28(1.09-1.52) | 24.5 | 1.61(1.10-2.34) | 0.0 |
| Ethnicity | ||||||||||||
| Asian | 6 | 651 | 1.26(0.78-2.03) | 0.0 | 1.08(0.21-5.47) | 0.0 | 1.31(0.77-2.23) | 0.0 | 1.27(0.76-2.13) | 0.0 | 1.05(0.21-5.28) | 0.0 |
| Caucasian | 15 | 1978 | 1.28(1.13-1.44) | 50.2 | 1.45(1.07-1.96) | 0.3 | 1.21(1.05-1.40) | 39.4 | 1.26(1.09-1.44) | 33.4 | 1.38(1.02-1.86) | 1.4 |
OR: odds ratio; CI: confidence intervals; S/F/NR: Sporadic/Familial/Not Report; E/L/NA: Early/Late/Not Available.